INOTROPIC AGENTS. ANTIANGINAL AGENTS. ANTIDYSRYTHMIC AGENTS
Inotropic Agents
Heart diseases can be primarily
grouped into three major disorders: cardiac failure, ischemia and cardiac
arrhythmia. Cardiac failure can be described as the inability of the heart to
pump blood effectively at a rate that meets the needs of the metabolizing
tissues. This occurs when the muscles that perform contraction and force the
blood out of heart are performing weakly. Thus cardiac failures primarily arise
from the reduced contractility of heart muscles, especially the ventricles.
Reduced contraction of heart leads to reduced heart output but new blood keeps
coming in resulting in the increase in heart blood volume. The heart feels
congested. Hence the term congestive heart failure. Congested heart leads to
lowered blood pressure and poor renal blood flow. This results in the
development of edema in the lower extremities and the lung (pulmonary edema) as
well as renal failure.
Heart Failure occurs when decreases in contractility prevent
the heart from contracting forcefully enough to deliver
blood to meet the demands of the body. Decreases in C.O. activate
reflex responses in the SNS which attempt to compensate for the reduced
C.O.: These reflex responses include 1. increases in heart rate (tachycardia),
2. increased preload (salt
and water retention increase blood volume through activation of the renin-angiotensin-aldosterone
pathway -this leads to peripheral and
pulmonary edema. Since the volume returned is greater than the ability
of the heart to pump, blood remains in the heart with each stroke leading to enlargement
of the heart), and 3. increased afterload
(through vasoconstriction via a receptors as well as through the production of
angiotensin II) resulting in compensated heart failure. Ultimately, SNS
activation can no longer compensate, and the heart fails. Drug treatment is directed towards 1) enhancing cardiac output with + inotropic drugs (cardiac
glycosides), 2) decreasing preload with diuretics and Angiotensin Converting
Enzyme (ACE) inhibitors , and/or 3) decreasing afterload with vasodilators like organic nitrates and ACE inhibitors.
Drugs to treat Heart Failure
DRUG/PHARMACODYNAMICS |
THERAPEUTIC VALUE |
|
decreased contractility (decrease
in ability of muscle to contract) results in SNS activation to compensate
for decreased cardiac output |
cardiac glycosides inhibit
the Na pump allowing Ca to inc. inside cells and increase the force of
contraction non-selective/b1-selective
agonists increase contractility |
Increase contractility increases cardiac
emptying, decreases preload, heart size and oxygen demand. Increase
C.O. decreases SNS tone, heart
rate and venous tone short-term
support of a failing heart
|
increased
preload due to Na/water retention caused
by activation of the renin - angiotensin - aldosterone
pathway. Na/water
retention lead to edema |
diuretics - increase Na and
water excretion ACE inhibitors -decrease
pro- duction of angiotensin II (a potent vasoconstrictor).
Decreased AngII decreases aldosterone thus decreasing salt and water
retention |
decreases preload (dec.
blood volume causes decreased venous return)
decreased afterload (dec.
AngII causes vasodilation or decreased PVR) and decreased preload due
to decreased aldosterone and increase Na and water excretion) |
increased vascular tone (increase
blood pressure) due to SNS activation in an attempt to compensate for
decreased contractility |
ACE inhibitors
- decrease production of AngII which is a
potent
vasoconstrictor
Nitrovasodilators
- dilate both veins and arteries |
decrease afterload due to arterial
dilation (dec. PVR) decrease preload and afterload due
to venous and arterial dilation, respectively |
Increasing
the force of contraction of the heart (positive inotropic activity) is very
important for most heart failure patients. There are several mechanisms by
which this could be achieved. Cardiac steroids are perhaps the most useful and
are being discussed here. Phosphodiesterase inhibitors, such as amrinone and
milrinone, have also been explored and so are direct adenylate cyclase
stimulants, such as forskolin. These drugs all act by affecting the
availability of intracellular Ca+2 for myocardial contraction or increasing the
sensitivity of myocardial contractile proteins.
The cardiac glycosides are an important class of
naturally occurring drugs whose actions include both beneficial and toxic
effects on the heart. Plants containing cardiac steroids have been used as
poisons and heart drugs at least since 1500 B.C. Throughout history these
plants or their extracts have been variously used as arrow poisons, emetics,
diuretics, and heart tonics. The therapeutic properties of cardiac glycosides
(eg, digoxin, a product of the foxglove plant) have been known since the days
of the
Purple Foxglove Lily of the valley
Lychnis Stophantus
Structure
Cardiac glycosides are composed of two structural features : the sugar (glycoside) and the non-sugar (aglycone
- steroid) moieties. (figure below)
The R group at the 17-position defines the class of cardiac
glycoside. Two classes have been observed in Nature - the cardenolides and the
bufadienolides (see figure below). The cardenolides have an unsaturated
butyrolactone ring while the bufadienolides have an a-pyrone
ring.
Nomenclature : The cardiac glycosides
occur mainly in plants from which the names have been derived. Digitalis
purpurea, Digitalis lanata, Strophanthus grtus, and Strophanthus kombe are the
major sources of the cardiac glycosides. The term 'genin' at the end refers to
only the aglycone portion (without the sugar). Thus the word digitoxin refers
to a agent consisting of digitoxigenin (aglycone) and
sugar moieties (three). The aglycone portion (figure below) of cardiac
glycosides is more important than the glycone portion. The steroid nucleus has
a unique set of fused ring system that makes the aglycone moiety structurally
distinct from the other more common steroid ring systems. Rings A/B and C/D are
cis fused while rings B/C are trans fused.
Such ring fusion give the aglycone nucleus of cardiac glycosides the
characteristic 'U' shape as shown below. To view the 3-dimensional
structure of the aglycone moiety click on the figure.
The steroid nucleus has hydroxyls at 3- and 14- positions
of which the sugar attachment uses the 3-OH group. 14-OH is normally
unsubstituted. Many genins have OH groups at 12- and 16- positions. These
additional hydroxyl groups influence the partitioning of the cardiac glycosides
into the aqueous media and greatly affect the duration of action. The lactone
moiety at C-17 position is an important structural feature. The size and degree
of unsaturation varies with the source of the glycoside. Normally plant sources
provide a 5-membered unsaturated lactone while animal sources give a 6-membered
unsaturated lactone.
Sugar moiety : One to 4 sugars are found to be present in most
cardiac glycosides attached to the 3b-OH group. The sugars most commonly used
include L-rhamnose, D-glucose, D-digitoxose, D-digitalose, D-digginose,
D-sarmentose, L-vallarose, and D-fructose. These sugars predominantly exist in
the cardiac glycosides in the b-conformation. The presence of acetyl group on the
sugar affects the lipophilic character and the kinetics of the entire glycoside.
Because the order of sugars appears to have little to do with biological
activity Nature has synthesized a repertoire of numerous cardiac glycosides
with differing sugar skeleton but relatively few aglycone structures.
Structure - Activity Relationships
Pharmacokinetics of
Cardiac Glycosides
The commercially available
cardiac steroids differ markedly in their degree of absorption, half-life, and
the time to maximal effect (see table below).
Agent |
GI absorption |
Onset (m) |
Peak (h) |
Half-life |
|
|
|
|
|
Ouabain |
Unreliable |
5-10 |
0.5-2 |
21 h |
Deslanoside |
Unreliable |
10-30 |
1-2 |
33 h |
Digoxin |
55-75% |
15-30 |
1.5-5 |
36 h |
Digitoxin |
90-100% |
25-120 |
4-12 |
4-6 days |
Usually
this is due to the polarity differences caused by the number of sugars at C-3
and the presence of additional hydroxyls on the cardenolide. Although two
cardiac glycosides may differ by only one sugar residue their partition
co-efficients may be significantly different resulting in different
pharmacokinetics. For example, lanatoside C and digoxin differ only by a
glucose residue and yet the partition co-efficient measured in CHCl3/16%
aqueous MeOH are 16.2 and 81.5, respectively.
Glycoside |
Partition Coefficient |
Lanatoside C
(glucose-3-acetyldigitoxose-digitoxose2-digoxigenin) |
16.2 |
Digoxin (digitoxose3-digoxigenin) |
81.5 |
Digitoxin (digitoxose3-digitoxigenin) |
96.5 |
Acetyldigoxin (3-acetyldigitoxose-digitoxose2-digoxigenin) |
98.0 |
G-Strophanthin (rhamnose-ouabagein) |
very low |
In general, cardiac
glycosides with more lipophilic character are absorbed faster and exhibit
longer duration of action as a result of slower urinary exretion rate.
Lipophilicity is markely influenced by the number of sugar residues and the
number of hydroxyl groups on the aglycone part of the glycoside. Comparison of
digitoxin and digoxin structures reveals that they differ only by an extra OH
group in digoxin at C-12, yet their partition coefficients differ by as much as
15 % points.
Biochemical Mechanism of Action
The mechanism whereby cardiac glycosides cause a
positive inotropic effect and electrophysiologic changes is still not
completely clear. Several mechanisms have been proposed, but the most widely
accepted involves the ability of cardiac glycosides to inhibit the membrane
bound Na+-K+-ATPase pump responsible for Na+-K+
exchange.
The process
of muscle contraction can be pictured as shown below.
The process of
membrane depolarization / repolarization is controlled by the movement of three
cations, Na+, Ca+2, and K+, in and out of the
cell. At the resting stage, the concentration of Na+ is high on the
outside. On membrane depolarization sodium fluxes-in leading to an immediate
elevation of the action potential. Elevated intracellular Na+
triggers the influx of free of Ca++ that occurs more slowly. The higher intracellular [Ca++] results in the efflux of
K+. The reestablishment of the action potential occurs later
by the reverse of the Na+-K+ exchange. The Na+
/ K+ exchange requires energy which is provided by an enzyme Na+-K+-ATPase.
Cardiac glycosides are proposed to inhibit this enzyme with a net result of
reduced sodium exchange with potassium that leaves increased intracellular Na+.
This results in increased intracellular [Ca++]. Elevated
intracellular calcium concentration triggers a series of intracellular
biochemical events that ultimately result in an increase in the force of the
myocardial contraction or a positive inotropic effect.
Digoxin
In 1785,
Withering published an account of digitalis (dried leaves of the purple
foxglove) and some of its medical uses.12 Although
digoxin continues to be viewed as beneficial in patients with heart failure and
atrial fibrillation, its role in patients with heart failure and sinus rhythm
has been increasingly challenged. Mackenzie and Christian, two eminent
clinicians and coeditors of Oxford Medicine, debated this issue in 1922.
Mackenzie advocated the use of digitalis only in heart failure with associated
atrial arrhythmias, whereas Christian argued that digitalis was effective
irrespective of an irregular pulse. In 1938, Cattell and Gold first showed a
direct inotropic effect of digitalis on cardiac muscle. For many more years,
digitalis continued to be an important part of heart failure management. The
detrimental aspects of digoxin therapy were not considered important until
excess mortality was reported in survivors of myocardial infarction who
received digitalis. Uncontrolled observations that the withdrawal of digoxin
produced no ill effects also raised concerns about the efficacy of the drug.
Pharmacology of digoxin
Action
§ Increases
vagal tone (central effect), leading to slowed ventricular response in atrial
fibrillation.
§ Reduces
sympathetic tone, especially when this is abnormally high, as in heart failure.
This is probably mediated partly via vagotonic actions and partly via direct
effects.
§ Positive
inotropic action mediated via direct blockade of Na+–K+-ATPase on cell membranes. This leads to
increased intracellular Na+ concentration,
which in turn increases intracellular Ca++
concentration via the Na+–Ca++
exchanger.
Negative Chronotropic Effect
of Digoxin
o
Decreases
ventricular response to atrial rate
o
Controls
heart rate in atrial fibrillation
Slows depolarization rate of
SA node
o Decreases sinus rate
o Decreases heart rate in Sinus Tachycardia
Digoxin in Patients with Mild to Moderate Heart
Failure
In the DIG trial, digoxin therapy
was most beneficial in patients with ejection fractions of 25 percent or lower,
patients with enlarged hearts (cardiothoracic ratio of greater than 0.55) and
patients in NYHA functional class III or IV. The findings of the DIG trial also
indicated that digoxin was clinically beneficial in subgroups of patients with
less severe forms of heart failure. Using direct clinical measures of heart
failure, the PROVED and the RADIANCE trials showed definite clinical
improvement in patients who were treated with digoxin, even patients with mild
heart failure. Based on the study findings, digoxin therapy may be effective in
patients with mild or moderate heart failure, although the magnitude of the
effect may be quite modest.
Digoxin in Patients with Preserved Left
Ventricular Systolic Function
Much has been learned about the
effective treatment of patients who have congestive heart failure associated
with left ventricular systolic dysfunction. In contrast, little is known about
how best to treat patients with preserved left ventricular systolic function. As many as 30 percent of patients with congestive heart failure
have a normal or nearly normal left ventricular ejection fraction. In
these patients, congestive heart failure is often described as "left
ventricular diastolic dysfunction." Left ventricular diastolic dysfunction
is considered to be a diagnosis of exclusion (or assumption) in patients with
congestive heart failure and preserved left ventricular systolic function.
Diagnostic tools such as radionuclide angiography and Doppler echocardiography
have made it possible to identify patients who have normal or nearly normal
left ventricular systolic function but abnormal left ventricular filling
parameters. The majority of patients with congestive heart failure who have
only diastolic dysfunction have no identified diagnosis. Most of these patients
are elderly or have a history of hypertension. Some patients have coronary
artery disease without extensive scar tissue. Such patients also commonly have
diabetes mellitus.
Approach to
Patients with Diastolic Dysfunction
In patients
with diastolic dysfunction, appropriate measures include the diagnosis and
treatment of myocardial ischemia (if present) and the aggressive treatment of
hypertension (if needed). Digitalis therapy has been considered inappropriate
in these patients. In some patients, treatment with diuretics and nitrates
could reduce pulmonary congestion. In the DIG trial, a subgroup of nearly 1,000
patients with a left ventricular ejection fraction of 45 percent or greater
experienced a reduction in congestive heart failure end points similar to
patients with a left ventricular ejection fraction of 25 to 45 percent. One
group of investigators suggested that this effect may be the result of
digoxin's ability to reduce neurohormonal activities. However, they concluded
that information about the effect of digoxin in patients with congestive heart
failure and preserved left ventricular systolic function is limited and does
not warrant routine use of the drug in this setting until the results of more
studies are available. At present, the consensus is that digoxin therapy is
probably inappropriate in patients with preserved left ventricular systolic
function. In addition, digoxin therapy may not be useful in patients with
congestive heart failure and a high cardiac output syndrome such as anemia or
thyrotoxicosis.
Adverse Effects of
Digoxin
Adverse reactions to digoxin are usually dose
dependent and occur at dosages higher than those needed to achieve a
therapeutic effect. The actual incidence of digoxin toxicity may be lower than
is historically reported. Adverse reactions are less common when digoxin is
used in the recommended dosage range and careful attention is given to
concurrent medications and medical conditions. The
principal manifestations of digoxin toxicity include cardiac arrhythmias
(ectopic and reentrant cardiac rhythms and heart block), gastrointestinal tract
symptoms (anorexia, nausea, vomiting and diarrhea) and neurologic symptoms
(visual disturbances, headache, weakness, dizziness and confusion). Most adult
patients with clinical toxicity have serum digoxin levels greater than 2 ng per
mL (2.6 nmol per L). Conditions such as hypokalemia, hypomagnesemia or
hypothyroidism may predispose patients to have adverse reactions even at lower
serum digoxin concentrations.
Dosages of Digoxin
Although
some investigators advocate the use of serum levels to guide digoxin dosing,
little evidence supports this approach.30 The
serum level of digoxin may be used to assist in evaluating a patient for
toxicity, but not to determine the efficacy of the drug. When digoxin was
considered to be mainly an inotrope, higher dosages (greater than 0.25 mg per
day) were generally used, and the incidence of toxicity was much higher. In the
PROVED and RADIANCE trials, the mean digoxin dosage was 0.375 mg per day.
However, a study of a subset of patients in the RADIANCE trial showed that
increasing the digoxin dosage from a mean of 0.2 mg per day to 0.39 mg per day
did not significantly improve heart failure symptoms, exercise time or serum
norepinephrine levels. When lower dosages are used, the side effects of
digoxin, especially ventricular arrhythmias, decrease. Use of lower dosages is
particularly important in the elderly, because digitalis toxicity may be difficult
to recognize in this patient population. It is generally agreed that digoxin
should be given in a dosage of 0.125 to 0.25 mg per day. Dosages higher than
0.25 mg per day are probably unwarranted. Renal function plays a major role in
the pharmacokinetics of digoxin and is an important factor in determining the
dosage. Medications such as quinidine, amiodarone (Cordarone) and verapamil
(Calan) can increase the serum digoxin concentration. Thus, safe and effective
dosing requires recognition of concomitant disease states and medications that
could change digoxin pharmacokinetics, along with a
recognition of digoxin toxicity.
Digoxin and Other
Medications for Congestive Heart Failure
ACE
inhibitors, beta blockers and spironolactone have been shown to improve
survival in patients with heart failure. Consequently, the role of digoxin in
the treatment of heart failure remains secondary, despite renewed interest in
its use. Digoxin has been shown to reduce the morbidity associated with
congestive heart failure but to have no demonstrable effect on survival.
In the absence of a
survival benefit, the goal of digoxin therapy is to improve quality of life by
reducing symptoms and preventing hospitalizations. Digoxin should be used
routinely, in conjunction with diuretics, ACE inhibitors, beta blockers and
spironolactone, in all patients with severe congestive heart failure and
reduced systolic function. It also should be added to the therapy of patients
with mild to moderate congestive heart failure if they have not responded
adequately to an ACE inhibitor or a beta blocker. If digoxin acts primarily by
reducing neurohormonal activation, its value is in question in patients with
heart failure who are already being treated with beta blockers.
Digoxin for
arrhythmia
While there is little doubt that
appropriate doses of digoxin will slow the resting ventricular rate in most
patients with chronic atrial fibrillation (E1), it has been known for many
years that digoxin is far less successful in controlling exercise-induced or
stress-induced tachycardia in atrial fibrillation in many patients, even when
plasma drug concentrations are near the upper end of the accepted therapeutic
range.1 A study of 12 patients with chronic atrial fibrillation confirmed that
medium-dose diltiazem was comparable, in terms of rate control at rest, to a
therapeutic dose of digoxin and superior to digoxin during exercise. High-dose
diltiazem (360 mg/day) was superior to digoxin, both at rest and during
exercise
Digoxin Toxicity
Toxicity
§ Common
(seen in 10%–20% of patients on long-term digoxin therapy).
§ Cardiotoxicity
is most serious and may manifest as ventricular or supraventricular
arrhythmias, including sudden increased prevalence of cardiac death (this was
almost exactly balanced in Digitalis Investigation Group trial by reduction in
"pump failure" deaths). Also, vagotonic actions can produce
bradyarrhythmias, including prolonged PR interval and high-grade heart block.
§ Non-cardiac
toxicity includes nausea, vomiting, diarrhoea, visual effects, including
"yellow" vision, and gynaecomastia.
Digitalis toxicity can occur
fairly easily and quickly. Digitalis can accumulate in tissues even when taken
as prescribed. Symptoms of digoxin toxicity are:
Several medications can affect
the way digitalis works, causing either an increase or decrease in the drug's
actions on the heart. Some of the medicines are:
Physicians
first studied digoxin in the 18th century. The syndrome of digoxin toxicity
originally was described in 1785.
Digoxin's inotropic effect results from the inhibition of the
sodium-potassium adenosine triphosphatase (NA+/K+ ATPase)
pump. The subsequent rise in intracellular calcium (Ca++) and sodium
(NA+) coupled with the loss of intracellular potassium (K+)
increases the force of myocardial muscle contraction (contractility), resulting
in a net positive inotropic effect.
Digoxin also increases the automaticity of Purkinje fibers but slows
conduction through the atrioventricular (AV) node. Cardiac dysrhythmias
associated with an increase in automaticity and a decrease in conduction may
result. The relationship between digoxin
toxicity and the serum digoxin level is complex; clinical toxicity results from
the interactions between digitalis, various electrolyte abnormalities, and
their combined effect on the Na+/K+ ATPase pump. Cardiac
glycoside toxicity from plants, such as oleander, foxglove, and
lily-of-the-valley, is uncommon but potentially lethal. Case reports of
toxicity from these sources implicate the preparation of extracts and teas as
the usual culprit.
Frequency:
The
overall incidence of digoxin toxicity has decreased because of a number of
factors including increased awareness of drug interactions, decreased use of
digoxin to treat heart failure and arrhythmias, and the availability of
accurate rapid radioimmunoassays to monitor drug levels.
Internationally:
Approximately 2.1% of inpatients on digoxin and 0.3%
of all admissions develop toxicity.
Mortality/Morbidity:
Age: Advanced age (>80
y) is an independent risk factor and is associated with increased morbidity and
mortality.
Digitalis toxicity
occurs in 5 to 20 percent of patients treated with digitalis glycosides.
Because the therapeutic and toxic ranges are relatively narrow, toxicity may
occur from an accidental overdose, unpredictable changes in renal function or
electrolyte imbalance. Most cases of digoxin toxicity are minor, and treatment
consists of temporary withdrawal or reduction in the dose. However, several
thousand patients each year require more aggressive treatment, often in the
coronary care unit. Mortality rates in patients with digoxin toxicity have
ranged from 3 to 25 percent. Digoxin immune Fab (ovine) fragments (Digibind)
have been shown to reverse digitalis toxicity and substantially reduce the risk
of death. Fab fragments are presently indicated for use in patients with
potentially life-threatening arrhythmias or other evidence of severe digitalis
intoxication. Such patients require continuous monitoring until digoxin levels
return to the therapeutic range. Mauskopf and Wenger used data from
uncontrolled studies of patients treated with Fab fragments and data from
symptomatically treated patients to estimate the difference in clinical
outcomes and medical care costs when Fab fragments are used. Treatment with Fab
fragments produces a greater reduction in mortality risk in patients with
serious toxicity than in patients with less serious toxicity. Treatment is
associated with increased total medical costs for patients with serious
toxicity, because more of these patients survive and require further
hospitalization and care. For these patients, the estimated cost per year of
life saved is between $1,900 and $5,400. When Fab fragments are used to treat
patients with less serious toxicity, total medical costs are decreased because
the number of days in the coronary care unit and the need for pacemakers and
other aggressive treatments are reduced.
Treatment of Toxicity
Amrinone
Mechanism(s) of Action
Increased force of contraction
Phosphodiesterase inhibition increased cyclic AMP in myocardial cell (same
biochemical effect as β-1,-2 stimulation)
Pharmacokinetics (humans)
Toxicity aggravates outflow
obstruction (contraindicated with aortic or pulmonic valvular disease,
hypotension (1.5%), arrhythmia (3% - consider other risks here),
thrombocytopenia (dose dependent - decreased platelet survival> nausea,
vomiting, abdominal pain, anorexia (1%), hepatic toxicity (9 - 32 mg/kg/day in
dogs - enzyme elevation, hepatic cell necrosis>, hypersensitivity
Clinical Uses
Topic Summary (Positive Inotropes)
1.
Cardiac glycosides
are definitely indicated for control of tachycardia associated with congestive
heart failure. The heart rate effects can be monitored (contractility effects
cannot).
2.
Cardiac glycoside
therapy is inherently risky and difficult. You will produce some toxicity in
some patients or you are not treating aggressively enough.
3.
Digoxin dosage must
be individualized for each patient.
4.
Bioavailability of
digoxin dose forms varies considerably (relative to the therapeutic index).
Patient monitoring should be increased when a change is made.
5. Non-glycoside inotropes are available for emergency
treatment. Some evidence exists to suggest that a short course of dobutamine
may have lasting (weeks) effects on patient performance.
Antianginal agents
Angina pectoris is chest pain
due to ischemia
(a lack of blood and hence oxygen supply) of the heart muscle,
generally due to obstruction or spasm of the coronary arteries (the heart's blood vessels).
Coronary artery disease, the main cause of
angina, is due to atherosclerosis of the cardiac arteries. The term
derives from the Greek ankhon
("strangling") and the Latin pectus
("chest"), and can therefore be translated as "a strangling
feeling in the chest".
An anginal pain attack signals a transient hypoxia of the
myocardium. As a
rule, the oxygen deficit results from inadequate myocardial blood
flow due to narrowing
of larger coronary arteries. The underlying causes are: most commonly, an atherosclerotic change
of the vascular
wall (coronary sclerosis with exertional angina); very infrequently, a spasmodic
constriction of a morphologically healthy coronary artery (coronary spasm with
angina at rest; variant angina); or more often, a coronary spasm occurring in an
atherosclerotic vascular segment.
http://www.musc.edu/bmt737/spring2001/Kate/angina2.html
The goal of treatment is to prevent
myocardial hypoxia either by raising
blood flow (oxygen supply) or by
lowering myocardial blood demand (oxygen
demand) (A).
Factors determining oxygen supply.
The force driving myocardial blood
flow is the pressure difference between
the coronary ostia (aortic pressure)
and the opening of the coronary sinus (right
atrial pressure). Blood flow is opposed
by coronary flow resistance, which
includes three components. (1) Due to their large caliber, the proximal coronary
segments do not normally contribute
significantly to flow resistance.
However, in coronary sclerosis or
spasm, pathological obstruction of flow
occurs here. Whereas the more common
coronary sclerosis cannot be overcome
pharmacologically, the less common
coronary spasm can be relieved by
appropriate vasodilators (nitrates, nifedipine).
(2)
The caliber of arteriolar resistancevessels controls
blood flow through the coronary bed. Arteriolar caliber is determined by myocardial O2
tension and local concentrations of
metabolic products, and is
“automatically” adjusted to the required blood flow (B, healthy subject). This metabolic
autoregulation explains why anginal attacks
in coronary sclerosis occur only
during exercise (B, patient). At
rest, the pathologically elevated flow resistance
is compensated by a corresponding
decrease in arteriolar resistance, ensuring adequate myocardial perfusion. During
exercise, further dilation of
arterioles is impossible. As a result, there is ischemia
associated with pain. Pharmacological
agents that act to dilate arterioles
would thus be
inappropriate because at rest they may divert blood from underperfused
into healthy vascular regions on
account of redundant arteriolar
dilation. The resulting “steal effect” could provoke
an anginal attack. (3) The
intramyocardial pressure, i.e., systolic squeeze, compresses the capillary bed.
Myocardial blood flow is halted during
systole and occurs almost entirely
during diastole. Diastolic
wall tension (“preload”) depends on ventricular volume
and filling pressure. The organic
nitrates reduce preload by decreasing venous return to the heart.
Factors determining oxygen demand.
The heart muscle cell consumes
the most energy to generate contractile
force. O2 demand rises with an increase
in (1) heart rate, (2) contraction
velocity, (3) systolic wall tension (“afterload”).
The latter depends on ventricular
volume and the
systolic pressure needed to empty the ventricle. As peripheral resistance
increases, aortic pressure rises, hence the resistance against which ventricular
blood is ejected. O2 demand is
lowered by â-blockers and
Ca-antagonists, as well as by nitrates. It is common to equate severity of angina with risk of
fatal cardiac events. There is a weak relationship between severity of pain and
degree of oxygen deprivation in the heart muscle (i.e. there can be severe pain
with little or no risk of a heart attack, and a heart attack can occur without
pain). Worsening ("crescendo")
angina attacks, sudden-onset angina at rest, and angina lasting more than 15
minutes are symptoms of unstable angina (usually grouped with similar
conditions as the acute coronary syndrome). As these may
herald myocardial infarction (a heart attack), they
require urgent medical attention and are generally treated as a presumed heart
attack.
Most patients with angina
complain of chest discomfort rather than actual pain: the discomfort is usually
described as a pressure, heaviness, tightness, squeezing,
burning, or choking sensation. Apart from chest discomfort, anginal pains may
also be experienced in the epigastrium (upper central abdomen), back, neck,
jaw, or shoulders. Typical locations for radiation of pain are arms (often
inner left arm), shoulders, and neck into the jaw. Angina is typically
precipitated by exertion or emotional stress. It is exacerbated by having a
full stomach and by cold temperatures. Pain may be accompanied by
breathlessness, sweating and nausea in some cases. It usually lasts for about 1
to 5 minutes, and is relieved by rest or specific anti-angina medication. Chest
pain lasting only a few seconds is normally not angina.
Myocardial ischemia comes
about when the myocardia (the heart muscles) fail to take in sufficient blood
and oxygen to function correctly. This inadequate perfusion of
blood and the resulting reduced delivery of oxygen and nutrients,
is directly correlated to blocked or narrowed blood vessels.
Some experience "autonomic
symptoms" (related to increased activity of the autonomic nervous system) such as nausea, vomiting and pallor. Major risk
factors for angina include cigarette
smoking, diabetes, high cholesterol, high blood
pressure and family history of premature heart
disease. A variant form of angina (Prinzmetal's angina) occurs in patients with
normal coronary arteries or insignificant atherosclerosis. It is thought to be
caused by spasms of the artery. It occurs more in younger women. Increase in
heart rate results in increased oxygen demand by the heart. The heart has a
limited ability to increase its oxygen intake during episodes of increased
demand. Therefore, an increase in oxygen demand by the heart (eg, during
exercise) has to be met by a proportional increase in blood flow to the heart.
Myocardial
ischemia can result from:
1.
a reduction of
blood flow to the heart caused by the stenosis or spasm of the heart's arteries
2.
resistance of
the blood vessels
3.
reduced
oxygen-carrying capacity of the blood.
Atherosclerosis
is the most common cause of stenosis (narrowing of the blood vessels) of the heart's
arteries and, hence, angina pectoris. Some people with chest pain have normal
or minimal narrowing of heart arteries; in these patients, vasospasm is
a more likely cause for the pain, sometimes in the context of Prinzmetal's angina and syndrome X.
Myocardial ischemia also can be
the result of factors affecting blood composition, such as reduced
oxygen-carrying capacity of blood, as seen with severe anemia (low number
of red blood cells), or long-term smoking.
Angina is more often the presenting symptom of coronary artery disease in women
than in men. The prevalence of angina rises with an increase in age. Similar
figures apply in the remainder of the Western world. All forms of coronary
heart disease are much less-common in the Third World, as its risk factors are much
more-common in Western and Westernized countries; it could therefore be termed
a disease of affluence. The increase of smoking,
obesity and
other risk factors has already led to an increase in angina and related diseases
in countries such as China.
Antianginal Drugs
Antianginal agents derive from three drug
groups, the pharmacological properties of which have already been presented in
more detail, viz., the organic nitrates, the Ca2+ antagonists, and the â-blockers.
Organic nitrates (A) increase blood flow,
hence O2 supply, because diastolic wall tension (preload) declines as venous return
to the heart is diminished. Thus, the nitrates enable myocardial flow
resistance to be reduced even in the presence of coronary sclerosis with angina
pectoris. In angina due to coronary spasm, arterial dilation overcomes the
vasospasm and restores myocardial perfusion to normal. O2 demand falls because
of the ensuing decrease in the two variables that determine systolic wall
tension (afterload): ventricular filling volume and aortic blood pressure.
Nitroglycerin (NG), also known as nitroglycerine, trinitroglycerin,
and glyceryl trinitrate, is a chemical
compound. It is a heavy, colorless, oily, explosive liquid obtained by nitrating glycerol. It is
used in the manufacture of explosives, specifically dynamite, and
as such is employed in the construction and demolition
industries, and as a plasticizer in some solid propellants.
It is also used medically as a vasodilator
to treat heart
conditions.Nitroglycerin was discovered by chemist Ascanio
Sobrero in 1847,
working under TJ Pelouze at the University of Torino. The best manufacturing
process was developed by Alfred Nobel in the 1860s. His company exported a
liquid combination of nitroglycerin and gunpowder as
'Swedish Blasting Oil', but it was extremely dangerous as a result of its
extreme instability, as shown in a number of "appalling
catastrophes," such as the explosion that destroyed a Wells Fargo
office in San Francisco in 1866. The liquid was widely banned,
and this led to the development of dynamite (and
similar mixtures such as dualine and lithofracteur), by mixing
the nitroglycerine with inert (Nobel used kieselguhr)
absorption (chemistry)|absorbents]] (e.g., nitrocellulose
gel, blasting
gelatine).
Nitroglycerin in medicine, where
it is generally called glyceryl trinitrate, is used as
a heart medication
(under the trade names Nitrospan®, Nitrostat®, and Tridil®,
amongst others). It is used as a medicine for angina
pectoris (ischaemic heart disease) in tablets,
ointment, solution for intravenous use, transdermal patches (Transderm
Nitro®, Nitro-Dur®), or sprays administered sublingually
(Nitrolingual Pump Spray®, Natispray®). The principal action of
nitroglycerin is vasodilation — that is, widening of the blood
vessels. The main effects of nitroglycerin in episodes of angina
pectoris are:
These effects arise because nitroglycerin is converted to
nitric
oxide in the body (by a mechanism that is not completely understood), and
nitric oxide is a vasodilatator).
Infrequent exposure to high doses of nitroglycerin can
cause severe headaches known as NG head: these headaches can be severe
enough to incapacitate some people; however, humans develop a tolerance and
addiction to nitroglycerin after long-term exposure. Withdrawal can (rarely) be
fatal; withdrawal symptoms include headaches and heart problems; with
re-exposure to nitroglycerin, these symptoms may disappear. For workers in
nitroglycerin manufacturing facilities, this can result in a "Monday
Morning Headache" phenomenon for those who experience regular
nitroglycerin exposure in the workplace; over the weekend they develop symptoms
of withdrawal, which are then countered by reexposure on the next work day.
Isosorbite mononitrate
The isosorbide mononitrate extended release
tablets product is an oral extended-release formulation of isosorbide
mononitrate, the major active metabolite of isosorbide dinitrate; most of the
clinical activity of the dinitrate is attributable to the mononitrate. The
principal pharmacological action of isosorbide mononitrate and all organic nitrates in general is relaxation of vascular smooth muscle, producing dilatation of peripheral arteries and veins, especially the latter.
Dilatation of the veins promotes peripheral pooling of blood, decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation
reduces systemic vascular resistance, and systolic arterial pressure and mean arterial pressure
(afterload). Dilatation of the coronary arteries also occurs. The relative importance of
preload reduction, afterload reduction, and coronary dilatation remains
undefined.
Isosorbide mononitrate is the major active
metabolite of isosorbide dinitrate, and most of the clinical activity of the
dinitrate is attributable to the mononitrate.
Pharmacodynamics
Dosing regimens for most chronically used
drugs are designed to provide plasma concentrations that are continuously greater than a
minimally effective concentration. This strategy is inappropriate for organic
nitrates. Several well-controlled clinical trials have used exercise testing to assess the
antianginal efficacy of continuously-delivered nitrates. In the large majority
of these trials, active agents were indistinguishable from placebo after 24 hours (or less) of continuous therapy. Attempts to overcome tolerance by dose escalation,
even to doses far in excess of those used acutely, have consistently failed.
Only after nitrates have been absent from the body for several hours has their
antianginal efficacy been restored.
Immediate Release Tablets
The drug-free interval sufficient to avoid
tolerance to isosorbide mononitrate has not been completely defined. In the
only regimen of twice-daily isosorbide mononitrate that has been
shown to avoid development of tolerance, the two doses of isosorbide
mononitrate tablets are given 7 hours apart, so there is a gap of 17 hours
between the second dose of each day and the first dose of the next day. Taking account
of the relatively long half-life of isosorbide mononitrate this result is
consistent with those obtained for other organic nitrates.
The same twice-daily regimen of isosorbide
mononitrate tablets successfully avoided significant rebound/withdrawal effects.
The incidence and magnitude of such phenomena have appeared, in
studies of other nitrates, to be highly dependent upon the schedule of nitrate
administration.
Extended Release Tablets
The isosorbide mononitrate extended release
tablets during long-term use over 42 days dosed at 120 mg once daily continued
to improve exercise performance at 4 hours and at 12 hours after dosing but its
effects (although better than placebo) are less than or at best equal to the
effects of the first dose of 60 mg.
Pharmacokinetics
In humans, isosorbide mononitrate is not
subject to first pass metabolism in the liver. The absolute bioavailability of isosorbide
mononitrate from isosorbide mononitrate tablets is nearly 100%. Maximum serum concentrations of isosorbide mononitrate are achieved
30 to 60 minutes after ingestion of isosorbide mononitrate.
The volume of distribution of isosorbide
mononitrate is approximately 0.6 L/Kg, and less than 4% is bound to plasma proteins. It is cleared from the serum by denitration to
isosorbide; glucuronidation to the mononitrate glucuronide; and
denitration/hydration to sorbitol. None of these metabolites is vasoactive.
Less than 1% of administered isosorbide mononitrate is eliminated in the urine.
The overall elimination half-life of
isosorbide mononitrate is about 5 hours; the rate of clearance is the same in
healthy young adults, in patients with various degrees of renal, hepatic, or cardiac dysfunction, and in the elderly. In a single-dose study,
the pharmacokinetics of isosorbide mononitrate were
dose-proportional up to at least 60 mg.
Nitroglycerine
Tolerance
Calcium antagonists (B) decrease O2
demand by lowering aortic pressure, one of the components contributing to afterload.
The dihydropyridine nifedipine is devoid of a cardiodepressant effect, but
may give rise to reflex tachycardia and an associated increase in O2 demand.
The catamphiphilic drugs verapamil and diltiazem are cardiodepressant. Reduced
beat frequency and contractility contribute to a reduction in O2
demand; however, AV-block and mechanical insufficiency can dangerously jeopardize
heart function. In coronary spasm, calcium antagonists can induce spasmolysis
and improve blood flow.
CCBs exert their clinical effects by blocking the L-class of voltage gated
calcium channels. By blocking transmembrane entry of calcium into arteriolar
smooth muscle cells and cardiac myocytes, CCBs inhibit the
excitation-contraction process. CCBs are a heterogeneous group of drugs.
Dihydropyridines are primarily potent vasodilators of peripheral and coronary
arteries. Non-dihydropiridines Verapamil and Diltiazem are moderate
vasodilators with significant cardiac effects
Adverse effects: Most
common side effect of CCBs is ankle edema. This is caused by vasodilatation,
which also causes headache, flushing and palpitation, especially with
short-acting dihydropyridines. Some of these side effects can be offset by
combining a calcium channel blocker with a beta blocker. Verapamil and
Diltiazem cause constipation. More seriously, they can cause heart block,
especially in those with underlying conduction problems. Verapamil, diltiazem
and short-acting dihydropyridines should be avoided in patients with heart
failure.
Amlodipine
Amlodipine (prolong acting) is a
dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker)
that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine
binds to both dihydropyridine and nondihydropyridine binding sites. The
contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the
movement of extracellular calcium ions into these cells through
specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on
vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact
animals at therapeutic doses. Amlodipine is a peripheral arterial vasodilator that acts directly on
vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.
The precise mechanisms by which amlodipine
relieves angina have not been fully delineated, but are thought to
include the following:
Exertional Angina: In patients with exertional angina,
Amlodipine reduces the total peripheral resistance (afterload) against which
the heart works and reduces the rate pressure product, and thus
myocardial oxygen demand, at any given level of exercise.
Vasospastic Angina: Amlodipine has been demonstrated to block
constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary
vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of NORVASC in
vasospastic (Prinzmetal’s or variant) angina.
â-Blockers (C) protect the heart against
the O2-wasting effect of sympathetic drive by inhibiting â-receptormediated increases in cardiac rate and speed
of contraction.
Beta-blockers
act by blocking the action of catecholamines at adrenergic receptors throughout
the circulatory system and other organs. BBs major effect is to slow the heart
rate and reduce force of contraction. BBs via
inhibition of
receptors at justaglomerular cells inhibit renin release.
Beta-blockers
may be classified based on their ancillary pharmacological properties. Cardioselective
agents have high affinity for cardiac β
and less affinity for bronchial and vascular β2 receptors compared with non-selective agents and this
reduces (but does not abolish) β 2 receptor-mediated side effects. However, with increasing doses cardiac selectivity
disappears. Lipid-soluble agents cross the blood-brain barrier more readily and
are associated with a higher incidence of central side effects. Some beta-blockers have intrinsic
sympathomimetic activity – ISA (i.e., they stimulate β
receptors when background sympathetic nervous activity is low and block them
when background sympathetic nervous activity is high). Adverse effects: BBs slow the rate of conduction at the
atrio-ventricular node and are contraindicated in patients with second- and
third-degree heart block. Sinus bradycardia is common and treatment should be
stopped if patient is symptomatic or heart rate falls below 40 b/min. Because
of blockade of pulmonary ß2 receptors, even small doses of BBs
can cause bronchospasm (less common with cardioselective agents), and all
beta-blockers are contraindicated in asthma. Blockade of ß receptors in
the peripheral circulation causes vasoconstriction and may induce particularly
in patients with peripheral circulatory insufficiency adverse affects such as
cold extremities, Raynaud’s phenomenon, and intermittent claudication.
Nevertheless, they are reasonably tolerated in patient with mild peripheral
vascular disease. Lipid-soluble agents can cause central nervous system side
effects of insomnia, nightmares and fatigue. Exercise capacity may be reduced
by BBs and patients may experience tiredness and fatigue. BBs can worsen glucose intolerance and
hyperlipidemia and in diabetic patients mask signs of hypoglycemia. However,
diabetic hypertensive patients with previous MI should not be denied BB because
of concerns about metabolic side effects.
Uses of antianginal drugs (D). For relief of the acute anginal attack, rapidly absorbed
drugs devoid of cardiodepressant activity are preferred. The drug of
choice is nitroglycerin (NTG, 0.8–2.4 mg sublingually; onset of action within
1 to 2 min; duration of effect ~30 min). Isosorbide dinitrate (ISDN) can
also be used (5–10 mg sublingually); compared with NTG, its action is somewhat
delayed in onset but of longer duration. Finally, nifedipine may be useful
in chronic stable, or in variant angina (5–20 mg, capsule to be bitten and the
contents swallowed).
For sustained daytime angina
prophylaxis, nitrates are of limited value because
“nitrate pauses” of about 12 h are appropriate if nitrate tolerance is to be
avoided. If attacks occur during the day, ISDN, or its metabolite isosorbide mononitrate, may be given in the morning and at noon (e.g., ISDN 40 mg in extended- release
capsules). Because of hepatic presystemic elimination, NTG is not
suitable for oral administration. Continuous delivery via a transdermal patch
would also not seem advisable because of the potential development of tolerance.
With molsidomine, there is less risk of a nitrate tolerance; however, due
to its potential carcinogenicity, its clinical use is restricted. The
choice between calcium antagonists must take into account the differential effect
of nifedipine versus verapamil or diltiazem on cardiac performance. When â-blockers are given, the potential consequences of
reducing cardiac contractility (withdrawal of
sympathetic drive) must be kept in mind. Since vasodilating â2-receptors are blocked, an increased risk of vasospasm cannot
be ruled out. Therefore, monotherapy with â-blockers is recommended only in angina due to coronary sclerosis, but not in variant angina.
Acute Myocardial Infarction
Myocardial infarction is caused by
acute thrombotic occlusion of a
coronary artery (A).
Therapeutic interventions
aim to restore blood flow in the
occluded vessel in order to reduce infarct size
or to rescue ischemic myocardial
tissue. In the area perfused by the affected vessel,
inadequate supply of oxygen and
glucose impairs the function of heart
muscle: contractile force declines. In
the great
majority of cases, the left ventricle anterior
or posterior wall) is involved. The decreased work capacity of the infarcted
myocardium leads to a reduction
in stroke volume (SV) and hence
cardiac output (CO). The fall in blood
pressure (RR) triggers reflex
activation of the sympathetic system. The resultant
stimulation of cardiac β-adrenoceptors elicits an increase in both heart
rate and force of systolic contraction,
which, in conjunction with an β-adrenoceptor- mediated increase in peripheral
resistance, leads to a compensatory rise in blood pressure. In
ATP-depleted cells in the infarct border zone, resting
membrane potential declines with a
concomitant increase in excitability
that may be further exacerbated by
activation of β-adrenoceptors.
Together, both processes promote the risk of fatal
ventricular arrhythmias. As a
consequence of local ischemia, extracellular concentrations of H+ and K+ rise in the
affected region, leading to excitation
of nociceptive
nerve fibers. The resultant sensation of pain, typically experienced
by the patient as annihilating,
reinforces sympathetic activation. The success of infarct therapy critically
depends on the length of time
between the onset of the attack and the
start of treatment. Whereas some
theraputic measures are indicated only after the diagnosis is confirmed, others necessitate
prior exclusion of contraindications
or can be instituted only in specially
equipped facilities. Without exception,
however, prompt action is imperative.
Thus, a staggered treatment
schedule has proven useful.
The antiplatelet agent, ASA, is
administered at the first suspected signs of infarction. Pain due to ischemia is treated
predominantly with antianginal
drugs (e.g., nitrates).
In case this treatment
fails (no effect within 30 min,
administration of morphine, if needed in combination with an antiemetic to prevent
morphine-induced vomiting, is
indicated. ECG If
ECG signs of myocardial infarction are absent, the patient is stabilized
by antianginal therapy (nitrates, β- blockers) and given ASA and heparin.
When the diagnosis has been confirmed
by electrocardiography, attempts
are started to dissolve the
thrombus pharmacologically
(thrombolytic therapy: alteplase or streptokinase) or to remove the obstruction by
mechanical means (balloon dilation or
angioplasty). Heparin is given to
prevent a possible vascular reocclusion, i.e.,
to safeguard the patency of the
affected vessel. Regardless of the outcome of thrombolytic therapy or balloon dilation,
a β-blocker is administered to suppress
imminent arrhythmias, unless it is
contraindicated.
Treatment of lifethreatening
ventricular arrhythmias
calls for an antiarrhythmic of the
class of
Na+-channel blockers, e.g., lidocaine.
To improve long-term prognosis, use is
made of a β-blocker ( incidence of
reinfarction and acute cardiac mortality) and an ACE inhibitor (prevention of
ventricular enlargement after
myocardial infarction) (A).
Antiarrhythmic agents
The past two decades have witnessed a rapid growth in understanding of
the cellular and molecular basis of both normal and pathological
electrophysiology. Elucidation of cardiac ion channel structure and
function has contributed to many of these advances.
As a result, we may be on the verge of an era where arrhythmia management
will no longer be dominated by trial and error based observational
treatment. Our aim in this article is to provide an overview of
antiarrhythmic drug action, linking known actions at the level of
cellular electrophysiology to clinical use. Taking particular
examples, we shall also illustrate how molecular genetic advances
have shown that some rhythm disturbances can result from specific
defects in genes encoding cardiac ion channels. Making reference to
investigational drugs under study, we will also consider the issue
of whether advances in the understanding of cardiac cellular
electrophysiology may improve rational approaches to antiarrhythmic
drug design and treatment.
http://heart.health.ivillage.com/arrhythmia/arrhythmia.cfm
The
mechanism of drug action is central to the process of choosing a drug to treat
any particular arrhythmia. Thus it is useful to consider first
impulse generation at the cellular level. This in turn demands
consideration of the ion channels underpinning impulse generation in
different cardiac muscle cell types. It is the opening and closing
of a range of different ion channels that leads to the distinct
profiles of membrane potential which comprise cardiac action
potentials. Therefore, we shall initially consider the
electrophysiological characteristics of cardiac action potentials,
aspects of ion channel function, and ion channels as sites of
antiarrhythmic drug action.
Membrane and action potentials: conventions shows
schematic representations of action potentials from pacemaker, ventricular, and
atrial tissues. Whereas the membrane potential in pacemaker cells
(typically from the sinus node, as this is usually the dominant
pacemaker) constantly cycles , cells
(myocytes) from ventricular and atrial
tissue ( possess true resting potentials, which usually lie
between 70
and
80 mV.
The negative value of the resting potential reflects the
dominant effect of a steady net efflux of positively charged K+
ions in these cell types by way of an ionic current (IK1), through
a channel type called the inward rectifier.1
Pacemaker cells from sinoatrial2
and atrioventricular nodes3
appear to lack a significant IK1, and as a resultalong
with other ionic currents
they
do not show a true resting membrane potential; rather, a pacemaker
potential precedes each action potential. Action potentials in all
cell types result from positive shifts in membrane potential (depolarisation),
caused by opening of ion channels, allowing positively charged
sodium and calcium ions to enter the cell through channels selective
for each ionic type. The rate of depolarisation during the action
potential upstroke in atrial and ventricular cells is faster than in
pacemaker cells, owing to the fact that a large
and fast sodium current underlies the upstroke in these cell types,
while the upstroke in pacemaker cells is predominantly carried by a
calcium current.
After
the peak of the action potential, the membrane potential is restored
to its original value during the repolarisation phase, as
channels passing depolarising current close and repolarising
channels (largely a range of potassium channels) open. Ventricular
cells in particular also possess a distinct plateau phase,
and the relatively long duration of the ventricular action potential
helps make the ventricular tissue refractory to overexcitation which
might otherwise tetanise the ventricular myocardium. The distinct
action potential phases discussed above are sometimes referred to as
phases 0 to 4: phase 0 is the action potential upstroke,
phase 1 is the early repolarisation "notch" (evident
immediately after the ventricular action potential peak , phases
2 and 3 describe plateau and late repolarisation (pacemaker
cell action potentials without a distinct notch or plateau may lack
distinct phases 1 and 2), while phase 4 is the period
after repolarisation is complete (the resting level in non-pacemaker
cells, and the pacemaker depolarisation in pacemaker cells).
Ion channels: the basics Critical to action potential
generation is the combined function of different membrane bound ion channels,
together with ion exchange proteins and ATP driven pumps. ATPases
for Na/K4
and Ca5
help sustain the normal transmembrane gradients for these ions, and
a sodium-calcium exchange protein contributes to calcium and sodium
homeostasis and membrane potential generation (for example, Allen
and colleagues,6
Janvier and Boyett7).
To
understand modifications of ionic currents by antiarrhythmic drugs, some
basic properties of ion channel function need to be examined. In
simple terms, transmembrane ion channels activated by membrane potential
changes can be viewed as proteins comprising a voltage sensor
coupled to a pore through which ions flow; the pore incorporates a
"selectivity filter" which determines which types of ions will pass
through the open pore.
FLOW OF IONIC CURRENT IN RELATION TO "EQUILIBRIUM POTENTIAL"
The direction of ion flow (and therefore of electrical current
generation) is determined by the transmembrane concentration gradient
established by the concentrations Co outside and Ci
inside the cell of the permeant ion, together with the electrical
gradient resulting from the membrane potential.
For a particular ionic species and given values of Co
and Ci, there will be one membrane potential value), at
which there is no net driving force for ions to flow across the
membrane. For example, for sodium ions ENa lies
near +70 mV; at potentials negative to this, sodium ions will
flow down their concentration gradient (from outside to inside the
cell) and generate a depolarising or inward current Beyond ENa
(a situation encountered experimentally, but not
physiologically), sodium ions would flow in the opposite direction
Conversely, for potassium ions, EK lies near
-90 mV, and at potentials positive to this potassium ions will
flow down their concentration gradient (from inside to outside the
cell) and generate repolarising or outward current .
If
the inside of the cell is made more negative than EK
the direction of ion flow will be reversed With a knowledge of the normal
intracellular and extracellular ion concentrations, it is possible
to predict the contributions of sodium, calcium, and potassium
channels in generating membrane potential depolarisation or
repolarisation.
One
further aspect of ion channel function should be covered before considering the
roles played by individual ion channel typeschannel gating. Voltage operated channels are
usually referred to as voltage gated, as biophysical measurements
indicate that specific membrane potential regulated processes
determine the magnitude and time course of ionic current flow across
the range of ion channel types. This can be explained by considering
an ion channel that does not pass current until a depolarising
stimulus is applied. At rest, the channel is therefore considered to
be closed. When a depolarising stimulus is applied, the membrane
potential change is detected by the voltage sensor
the
channel undergoes a conformational change and opens in order to allow
ionic current to flow.
The process describing
the transition from the closed to open state is termed activation.
The probability of channels moving to the open state usually depends
on the magnitude of the voltage change (activation is therefore "voltage
dependent"), and the speed with which channels move from the
closed to the open state will determine the rate of activation.
Some voltage dependent channels show only a voltage dependent activation
process, but for many a second process also influences ionic current
flow. If the depolarising stimulus is maintained, a second
conformational change occurs in the ion channel. Part of the ion
channel protein moves to occlude the channel pore such that, while
the channel may be fully activated, it becomes poorly conducting. This
process, which, like activation, is voltage and time dependent, is termed inactivation.
Experimentally, the properties of channel activation, inactivation,
voltage sensitivity, and ionic selectivity can be studied using
voltage or patch clamp techniques. The important points here are as
follows:
Drugs which bind preferentially to open or inactivated
channel states may exert effects that vary with stimulation frequency (or
in vivo, with heart rate) and as such can show use dependence. For antiarrhythmic agents, an ideal channel blocking agent would have
positive use dependenceshowing a greater inhibitory action at faster heart
rates. Drugs binding preferentially to closed channels may either
exert use independent actions or show "reverse use
dependence," in which the drug dissociates from its binding site
during channel activation. With reverse use dependent
blockade, faster rates of channel stimulation (or indeed heart rate)
encourage greater dissociation than slower rates, resulting in
comparatively less channel inhibition at faster than at slower rates.
CHANNELS INVOLVED IN PACEMAKING
In the sinus node, the T type calcium
current (ICa,T) and the hyperpolarisation activated current (If)
both provide inward, depolarising current during the pacemaker
depolarisation2
that precedes each action potential upstroke (fig 1A). Agents
that reduce these currents should therefore slow the rate of the
pacemaker depolarisation and thereby have a negative chronotropic
effect. Specific inhibitors of If produce rate reduction.9 10
Mibefradil is a blocker of ICa,T which preferentially relaxes
coronary vasculature and slows heart rate without reducing
contractility,11
making it a potential bradycardic agent. This particular compound
was voluntarily withdrawn because it was involved in several
clinically relevant drug interactions.12
In general, the use of selective bradycardic agents is likely to be
of limited value except in inappropriate sinus tachycardia.
CHANNELS INVOLVED IN ACTION POTENTIAL DEPOLARISATION
L type calcium and sodium channels
are of greater importance as antiarrhythmic targets.
The importance of INa in generating the
fast upstroke phase of both atrial and ventricular action potentials makes INa
blockers potentially effective against both supraventricular and
ventricular arrhythmias. Sodium channel-drug interactions are
usefully considered within the "modulated receptor" model,
which takes into consideration the channel state to which a drug
preferentially binds.8 18 The action potential upstroke
rate can become slowed when INa is reduced and as a
result INa blockers can decrease impulse conduction velocity.
In addition, agents that delay the recovery of INa from channel
inactivation have the effect of prolonging tissue refractoriness.
Agents such as quinidine,19 propafenone,20 and disopyramide21 preferentially bind to the open (activated) state of
the sodium channel, while others including lignocaine
(lidocaine)22 and
mexiletine23 show a preference for the inactivated channel.
Open channel blockers are effective in generally reducing electrical
excitability and impulse conduction, while inactivated channel blockers
may show a blocking effect influenced by differences in atrial and
ventricular action potential profile (fig 1). The comparatively
longer and more depolarised ventricular action potential plateau
results in a more prolonged inactivation of INa, with an
increased level of block. This property may contribute to the selectivity
of drugs such as mexiletine against ventricular arrhythmias; it
might also be used in combination treatment by combining an inactivated
state sodium channel blocker with a drug that delays repolarisation,24
resulting in enhanced sodium channel inhibition and thereby
prolonged refractoriness.
The kinetics of recovery from block are also critically important in determining the effects of
sodium channel blockers. Agents associated with slow recovery from
block (for example, flecainide25)
cause a block that accumulates rapidly on repetitive stimulation, and
a stable steady state level of block is attained over a wide range
of heart rates.26
Agents with relatively fast recovery from block (for example,
mexiletine) may show little cumulative block at slow heart rates, as
block is relieved between action potentials.
At faster rates (tachycardias), block accumulates
because there is too little time for unbinding to occur between action
potentials. This produces the effect of "positive use dependence,"
which is beneficial in that little ECG alteration may be experienced
at normal rates, whereas drug effects become important during tachyarrhythmias.
It is important to realise, however, that blocking
efficiency and recovery can be affected by various factors. Open channel blockers
may be less effective in damaged or ischaemic tissue; this is often
depolarised, resulting in the inactivation of a proportion of
channels, thereby rendering these unavailable for block. In
contrast, inactivated state blockers may be more effective in
conditions where tissue becomes depolarisedexperimental
evidence suggests that the efficacy of lignocaine and the risk of
proarrhythmia are both enhanced in acutely ischaemic myocardium.27
In addition to the effects of membrane potential depolarisation on
block, the low pH associated with ischaemia can also slow the time
constant of drug dissociation, enhancing the cumulative level of
channel block.26
POTASSIUM CHANNELS
Some sodium channel blocking agents,
for example disopyramide28
and in particular quinidine,29
are also associated with delayed repolarisation and QT prolongation on
the ECG. For both disopyramide30
and quinidine,31 32
this effect results from potassium channel blocking actions of the
drug. Excessive action potential and QT prolongation (when the
corrected QT interval (QTc) exceeds ~44029
to 46033
ms), carries a risk of proarrhythmia. However, potassium channel
blockade can also be antiarrhythmic, because moderately delayed
action potential repolarisation can enhance the inactivation of
depolarising currents (INa and ICa), thereby
prolonging the period between successive action potentials. This can
be effective in disrupting arrhythmias caused by reentrant mechanisms.
Different potassium channel types, therefore, offer potential
antiarrhythmic drug targets. Major potassium ion channel types
involved in action potential repolarisation include the transient
outward current, ITO, responsible for the action potential notch
in ventricular cells and prominent during atrial repolarisation.1 34 The rapid and slow components of delayed
rectifier current (IKr and IKs, respectively35)
are important in plateau repolarisation.36 37 The inward rectifier potassium
current is important for the final stage of repolarisation37 38
and for maintaining the cell resting potential. Owing to their roles
in plateau repolarisation, IKr and IKs are of
particular interest as antiarrhythmic targets.
As in the case of sodium channel blocking agents, the
desirable potassium channel blocker is one that shows positive use dependence
(that is, the drug effects are greatest at faster action potential rates).
Unfortunately, many potassium channel blocking drugs appear to be
associated with a reverse use dependent effect: action potential prolongation
is greater at slower rather than at faster rates.39 The
problem with this is that action potential prolongation at slow
rates can be proarrhythmic through the cellular mechanism of early
afterdepolarisations. By a mechanism originally investigated by
January and Riddle40
and recently reviewed by Makielski and January,41
sufficiently slowed membrane repolarisation during the action
potential facilitates calcium entry through L type calcium channels,
which can result in early afterdepolarisations. These in turn could
give rise to triggered activity and lead to torsade de pointes.
Selective block of IKr (for example, by the drug E-4031)
can be sufficient to induce early afterdepolarisations.42 Early
afterdepolarisations are relieved at faster rates; therefore IKr
block is most likely to be proarrhythmic at slow rates. The clinical
implications of reverse use dependence and specific IKr
block are exemplified by sotalol which, as the racemic D-L mix, possesses
blocking and IK blocking actions and
is indicated for the treatment of life
threatening ventricular tachycardia. Racemic sotalol produces some
QT prolongation and is bradycardic.43 D-sotalol
lacks the
blocking
activity of the racemic mix, but is an IKr blocker35
and shows reverse use dependent effects on the action potential.44
Significantly, D-sotalol is associated with an increased risk of
death from presumed arrhythmias.45
A simple explanation for reverse use
dependent drug effects on action potential prolongation involves drug binding
to the resting channel (in the interval between action potentials)
and dissociating during membrane depolarisation.46
This would produce a greater relief of block at faster rates (at
which there would be shorter intervals between action potentials for
drug binding to occur). However, subsequent experiments on cloned
channels are not consistent with this explanation (for example,
Synders and colleagues47).
Moreover, agents such as almokalant block IKr in a use
dependent fashion,48
while producing reverse use dependent action potential prolongation.24
In addition, dofetilide has been reported to produce rate
independent effects on IKr, but reverse rate dependent
effects on the action potential.49 In
the same study,49
repetitive stimulation was observed to increase the magnitude of IKs
but not of IKr. It has been proposed, therefore,
that reverse use dependence may result from the interaction between
IKr and IKs during repolarisation at different heart
rates.49 At
slower rates IKr may be dominant; at faster heart rates the role
of IKs increases owing to incomplete deactivation (the transition
of channels from OC, fig 3A) of the
current between action potentials. Thus specific IKr
inhibition would have a greater effect on repolarisation at slower
than at faster rates.
If this mechanism holds, then an agent which blocks IKs specifically might be better for
treating tachycardias than an IKr blocker; moreover, an
agent that blocks both components of IK might have an
improved safety profile over a specific IKr blocker. There
are few experimental data yet available to support the first of
these possibilities (selective IKs blockers are only beginning to
appear); the second, however, does seem to hold true. Quinidine and
sotalol do not appear to block IKs.50
By contrast amiodarone, which has a much better cardiac safety profile, blocks
both IKr and IKs,50 51
while also showing a more consistent effect on action potentials at
different rates.52
Side effects
of amiodaron
A
further potassium channel should be mentioned, as it is likely to mediate the
antiarrhythmic actions of adenosine. The extremely short half life
of adenosine makes intravenous administration valuable in
terminating tachycardias involving the AV node (either AV nodal
re-entry or AV re-entry). In bolus form, adenosine
has been shown to be highly effective against paroxysmal
supraventricular tachycardias that require AV nodal conduction for
their maintenance.53 54 The cellular basis for the effect
of adenosine appears to resemble that for acetylcholine. Acetylcholine activates a potassium
current (IKACh), which is important in mediating parasympathetic
effects on the sinoatrial2
and AV nodes.55
When activated, IKACh produces membrane potential hyperpolarisation;
it thereby decreases automaticity and excitability. At the cellular
level, adenosine activates a current (IKAdo) with
properties identical to those of IKACh (for example,
Belardinelli and colleagues56).
Cellular studies on rabbit AV node suggest that activation of IKAdo
is likely to be predominantly responsible for the action of
adenosine, with possible supplementary effects on L type calcium
channels.57 58
Amiodaron Thyroiditis
Molecular insights into arrhythmogenesis Some of the most exciting cardiological developments of the
last decade relate to advances in understanding the molecular biology
underlying ion channel function, and the finding that defects in
individual ion channels can underlie particular arrhythmias. This is
no better exemplified than in congenital long QT syndrome. This
syndrome illustrates how various different channelopathies can
manifest themselves clinically as virtually identical electrocardiographic
endpoints. Congenital long QT syndrome is characterised by abnormally
prolonged ventricular repolarisation leading to QTC
prolongation (as discussed earlier), with an associated risk of
malignant ventricular tachyarrhythmias (torsade de pointes).
Congenital long QT syndrome has been found to arise
from a range of different genetic abnormalities33 59-67
(table 1). The two
main forms are the autosomal dominant Romano-Ward syndrome (pure
cardiac phenotype)68
and the autosomal recessive Jervell-Lange-Nielsen syndrome (in which
cardiac abnormalities coexist with congenital deafness).69
Of the genetic abnormalities identified in the Romano-Ward syndrome,
four are associated with identified ion channels. Most of the
mutations causing congenital long QT (LQT) syndrome are missense
mutations. However, substantial phenotypic heterogeneity remains,
even with identical gene abnormalities. LQT1, 2, and 3 all
result in prolongation of the action potential. The extent of
prolongation depends not only upon the gene mutated, but also upon
the exact location of the mutation.33 70
As discussed earlier, it is the risk of afterdepolarisations
associated with QT interval prolongationrather
than slowing of action potential repolarisation on its own
that
is arrhythmogenic. The involvement of L type ICa in the
production of early afterdepolarisations and the widely known
enhancement of ICa by
adrenergic
stimulation may, at least in part, explain the clinical
effectiveness of
blockers
in reducing the incidence of syncopal episodes and arrhythmias in
the long QT syndrome.33 70
As shown in table 1, alterations
in the genes underlying IKr and IKs are associated with
LQT-2 and LQT-1. The channels for both IKr and IKs
are multimeric,36
and alleles from both parents contribute to the channel complexes.
Mutant channels expressed in oocytes or cell lines show loss of
function.61
Channel kinetics, as well as reduced overall current, contribute to the loss of function (that is, a
reduction in repolarising outward current). In contrast, mutations
of sodium (SCN5A) channels cause a gain of function,71 72
in which a late persistent (depolarising) sodium current is produced
because of defective inactivation of INa. Owing to the
heterogeneous basis for congenital long QT syndrome, identification
of the underlying cause is pivotal in deciding upon appropriate
treatment. Provocation may distinguish between the different
congenital LQT syndromes. While the QT interval shortens only
minimally with exercise in LQT1 and LQT2, in patients with LQT3 it
shortens significantly.70 73
Furthermore, torsade de pointes is precipitated by adrenergic
stimulation (for example, during exercise) in LQT1, possibly because
IKs normally predominates at high rates, and therefore
reduced IKs would lead to inadequate shortening of the
action potential.70
In contrast, most patients with LQT 3 experience more events at
rest than on exertion.70 73
Another interesting group of patients providing a
clear link between cellular abnormalities and clinical treatment are those
with the Brugada syndrome.74 75 These patients have structurally normal hearts
and right precordial ST segment elevation or right bundle branch
block.76
The ECG abnormalities probably reflect exaggerated transmural
differences in action potential configuration, especially within the
right ventricular outflow tract. The end result is an increased risk
of ventricular fibrillation within these families. One variant of
the Brugada syndrome arises from a mutation of the SCN5A gene (the
same gene that is implicated in LQT3),77
leading to a gain of function; hence drugs targeting the sodium
channel may be clinically effective.
IMPLICATIONS OF
GENETIC INSIGHTS?
In addition to the syndromes
described above, our understanding of the role of genes in other conditions has
also increased. The reader is referred to a recent and comprehensive
review by Priori and colleagues.70.
A clear result of the arrival of molecular biology in the clinical
arena is that genetic testing may be available not only for
diagnostic purposes in patients presenting with arrhythmias but also
possibly for individuals who could benefit from prophylactic treatment
to avoid sudden death. Increased genetic knowledge may also
influence treatment strategy. For example, sodium channel blockers
such as lignocaine and mexiletine may be effective in LQT-3,71 72
while LQT-2 would be expected to be respond to a different approach.
Cloned channels encoded by HERG (the gene underlying channels for IKr)
show currents that increase in size as external potassium
concentration ([K]e) is raised and decrease as [K]e
is lowered.60
Consistent with this experimental observation,
However, while long QT syndrome and the Brugada
syndrome may provide a clear route from cell to clinic, some common arrhythmias
are not yet so accommodating. Refractory arrhythmias, for example, may
be refractory because of the complex processes involved in their
pathogenesis. These may include both electrical and structural remodelling.
Electrical remodelling may be physiological and unrelated to cardiac
disease (for example, atrial fibrillation may become self sustaining79),
or pathological in origin (alteration in the distribution of gap
junctions between cells in diseased tissue80).
Structural remodelling may also be either physiological (for example,
initial ventricular hypertrophy in response to hypertension) or pathological
(cell hypertrophy in peri-infarct zones and cell loss with
replacement fibrosis within infarcted regions81).
Therefore complex arrhythmias with a multifactorial aetiology may
benefit from primary prevention targeted towards alleviation of
diseases such as coronary occlusion or ventricular hypertrophy. A
second line of attack may then be directed towards the electrophysiological
sequelae of upstream events. Treatment must be tailored towards the
aetiology of the arrhythmia, as drug treatment for ventricular tachycardia
in one patient may be detrimental in another. Indeed, in the
structurally abnormal heartfor
example, after myocardial infarction or during congestive cardiac
failure
drug
efficacy has been limited and in these conditions antiarrhythmic
drugs can have a significant proarrhythmic potential.82-84
Re-evaluation
of antiarrhythmic drug classification Another area that has experienced change owing to the
increased information available from cellular cardiology is that of drug
classification. Early approaches to antiarrhythmic drug development involved
the identification of natural compounds with antiarrhythmic activity
such as cinchona,85
or identification of antiarrhythmic effects of drugs licensed for
other uses, primarily local anaesthetics, including lignocaine and
its derivatives. Clinical studies verified the acceptability as
antiarrhythmic agents of synthetic molecules such as procainamide.86
Further attempts were than made to produce related compounds with
increased potency and reduced toxicity (for example, flecainide,
lorcainide, and encainide82 87).
While this approach has provided many useful drugs for therapeutic use,
the derived compounds have to varying degrees retained the adverse
effect profiles of parent drugs. Progress in the development of
newer antiarrhythmic drugs has not been as great as once anticipated, and
the chance discovery of antiarrhythmic properties of drugs developed
for other conditionsfor
example, amiodarone (initially developed as an antianginal drug)
has
contributed significantly to the armoury available to the clinician.
In 1970, Vaughan Williams proposed a
classification based on possible ways in which abnormal cardiac rhythms could
be corrected or prevented.88 89 In this early classification, class I drugs act
by reducing inward sodium current at concentrations not affecting the
resting membrane potential. Class II drugs act by blocking sympathetic
activity of the heart. Although not thought to affect the action
potential of most myocardial cells, these drugs reduce the
spontaneous rate of depolarisation of pacemaker cells under adrenergic
stimulation and are therefore negatively chronotropic. They are also
negatively dromotropic, as the AV node tends to be under greater
sympathetic drive than the sinoatrial node for which vagal tone
normally predominates. Class III drugs prolong action potential
duration. They do not specifically affect any single factor involved
in repolarisation (although in reality most class III drugs exert
potassium channel blocking actions). They are able to alter the activity
of several different ion channel conductances at a cellular level,
making their impact upon the action potential quite complex. In
general, they prolong action potential duration and hence prolong
the length of the refractory period. In a separate class was placed
diphenylhydantoin, a centrally acting drug.
In 1974, Singh and Hauswirth
modified the classification, with two major changes.90
First, lignocaine and diphenylhydantoin were placed in a separate
class, because at low concentrations and at low external potassium
concentrations, they had little effect upon the action potential or
cardiac conduction. Secondly, a separate class (now denoted class
IV) was introduced to accommodate calcium channel blockers, which
(as described earlier) predominantly affect regions in which action
potential depolarisation depends on
The "Singh-Hauswirth-Harrison-Vaughan
Williams" (S-H-H-VW) classification is summarised in table 2. Many
antiarrhythmic drugs have more than one class of action (for
example, racemic sotalol has class II and class III activity and
amiodarone has class I-IV actions). Moreover, some drugs within a
particular class may differ in their clinical effects owing to
subtle (but significant) differences in their mechanism of action at
the ion channel level. In addition, there are some antiarrhythmic
drugs (for example, digoxin and adenosine) which cannot be fitted
into the S-H-H-VW I-IV classification.
While the S-H-H-VW classification has been valuable,
the limitations of inadequate correlations between drug mechanism, arrhythmia
mechanism, and therapeutic efficacy gave rise to the "Sicilian Gambit"
approach to antiarrhythmic treatment. This approach to arrhythmia
management, formulated by the European Society of Cardiology working
group,94
seeks the critical mechanisms responsible for arrhythmogenesis
(table 3) to identify
a "vulnerable parameter" or "Achilles heel" of
the arrhythmia concerned. This would enable the clinician to select
a drug on the basis of its mechanism of action and not empirically.
This approach complements well those recent advances in our
understanding of molecular biology (for example, cloning and
sequencing of ion channels and receptors) that have raised hopes for
a "target oriented" approach to antiarrhythmic treatment.
There are, however, two fundamental issues that might hinder this
approach to drug selection. First, an Achilles heel is not always
(yet) identifiable for many arrhythmias, and in some cases there may
be more than one Achilles heel, some of which are not involved in
arrhythmogenesis. In addition, there are drugs classified within the
S-H-H-VW classification that have multiple electrophysiological
targets; this may preclude them from being selective for any one
particular Achilles heel. Second, consideration of drug action based
on multiple targets (ion channels, receptors, and second messenger
systems) and the "spread sheet" approach advanced in the
Sicilian Gambit94
generates a degree of complexity absent from the S-H-H-VW
classification, and which may hinder acceptance of this approach.95
Against this, however, a major advantage of the Sicilian Gambit
approach is that it provides a framework within which the ever
increasing information on arrhythmogensis and drug action can be
readily accommodated and considered.(for example, Members of the
Sicilian Gambit96)
Our
increasing knowledge of the basic electrophysiological and genetic
characteristics of ion channels, the cellular actions of
antiarrhythmic agents, their effects on animal models, and the
results of clinical trials should help guide future rational drug
development and classification. In a recent article,97 Camm
and Yap summarise attributes for future antiarrhythmic agents, including:
appropriate modification of the arrhythmia substrate, suppression of
arrhythmia triggers, efficacy in pathologic tissues and states,
positive rate/use dependent effects, similar efficacy in oral and
parenteral formulations, similar efficacy in arrhythmias and their
surrogates, few side effects, and cardiac selective ion channel
blockade.
One of the central issues will be whether approaches
which focus on a single ion channel target offer more promise than approaches
based on compounds with "polypharmacological" (multiple ion
channel) effects. Recently discovered ion channelssuch
as the ultrarapid delayed rectifier (IK,ur)
in atrial tissue98
may
offer new, alternative drug targets. Importantly, the reverse use
dependence associated with some drugs with class III (predominantly
IKr) blocking actions might be taken as suggesting that
either drugs against alternative targets to IKr or drugs
with multiple effects may be superior to selective IKr
blockers alone.
Unfortunately, the emerging picture
is not as clear as this. While the results of the SWORD (survival with oral
d-sotalol) trial indicate that d-sotalol increases mortality and is
therefore unsuitable for use,45
the same does not appear to be true for dofetilide. Dofetilide is a
potent and selective blocker of IKr, which, although
associated with reverse use dependent effects on the action
potential at the cellular level,49
has a profile that is not clearly reverse use dependent in humans
(for example, Bashir and colleagues99).
The drug appears to be reasonably well tolerated and at some
concentrations is effective at suppressing ventricular tachycardia.99
Moreover, its use does not seem to be associated with significantly
increased mortality, and with only a low incidence of torsade de pointes.100
Quite why dofetilide appears to be safer than d-sotalol is not
entirely clear, though there is some experimental evidence that the
class III effects of d-sotalol are much more sensitive to
extracellular potassium levels than those of dofetilide.44
At this stage, it would appear premature to rule out selective IKr
blockade as a viable antiarrhythmic strategy.
IKs blockade may, in principle, offer an
attractive alternative or supplementary approach to IKr inhibition. Azimilide is a relatively new agent effective
at inhibiting both IKr and IKs.101 Data
from experiments in which IKs blocking effects of the drug on
the action potential have been estimated suggested that the IKs
block alone was associated with rate independent action potential prolongation.102
The overall drug effect on the action potential (involving combined
IKr and IKs actions) shows some variations between
experimental studies, with reports of either some reverse use
dependence102 103
or a rate independent action on effective refractory period.104 Azimilide may be effective against both atrial
and ventricular arrhythmias101 104
and, while it is too early to comment with certainty on its efficacy
and safety in humans, initial signs appear promising.101
Several clinical trials including the ALIVE (azimilide post-infarct
survival evaluation) study105
were ongoing at the time of writing.
Other investigative agents with polypharmacological
effects include ibutilide and tedisamil. Ibutilide has an interesting pharmacological
profile in that in addition to affecting IKr it also
appears to induce a sustained sodium current, an
effect that would be synergistic in prolonging the action potential.106
Tedisamil blocks IKr and the transient outward potassium
current (ITO).107 It
has been shown to be effective against ventricular fibrillation in a
rabbit model108
and it prolongs the monophasic action potential in humans.109
Dronedarone, an investigational drug related to amiodarone, may be
an agent of particular interest.97
Like its parent compound, dronedarone may be expected to exert
multiple S-H-H-VW effects and thereby have wide ranging efficacy.
The results of trials of this and other agents with
polypharmacological effects will be important in the debate about
whether the future development of antiarrhythmic agents lies in
single or multiple ion channel targets. As the underlying basis for
the generation and maintenance of particular arrhythmias becomes
increasingly understood, so will our understanding of the nature of
any associated Achilles heel or vulnerable parameter. This
knowledge, together with ongoing revision of drug classification
according to target/action, is likely to refine pharmacotherapeutic
approaches to clinical arrhythmia management.
This work was supported by grants
from the British Heart Foundation, the United Bristol Healthcare Trust, and the
Wellcome Trust. KCRP was supported by a British Heart Foundation
clinical training fellowship, and JCH was supported by a Wellcome
Trust research fellowship. We thank Kathryn Yuill for providing the
ionic current record for figure 3B, and Helen
Wallis for comments on the manuscript.